CrystagenvsSS-31

Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.

Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.

As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.

SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable, mitochondria-targeted tetrapeptide with an alternating aromatic-cationic motif that drives its remarkable 1,000-fold concentration within mitochondria. This accumulation is driven by the highly negative mitochondrial membrane potential (-180 mV), which electrostatically attracts the cationic peptide, and by its lipophilic aromatic residues which partition into the inner mitochondrial membrane.

Once concentrated in the inner mitochondrial membrane, SS-31 selectively binds to cardiolipin — a unique dimeric phospholipid found almost exclusively in this membrane. Cardiolipin plays an essential structural role: it anchors cytochrome c to the inner membrane surface, optimizing electron transfer between Complex III and Complex IV of the electron transport chain (ETC). With aging and disease, cardiolipin undergoes peroxidation by reactive oxygen species (ROS), which disrupts its interaction with cytochrome c. Loosened cytochrome c transfers electrons less efficiently, increasing electron leak to molecular oxygen and generating more ROS — creating a vicious cycle of mitochondrial decline.

SS-31 breaks this cycle by stabilizing the cardiolipin-cytochrome c interaction, restoring optimal electron transfer efficiency and reducing ROS generation at the source. It also protects cardiolipin from peroxidation by ROS scavenging through its dimethyltyrosine (Dmt) residue. The downstream effects are profound: restored mitochondrial membrane potential, improved ATP production, reduced oxidative damage to mitochondrial DNA and proteins, and prevention of the mitochondrial permeability transition pore (mPTP) opening that triggers apoptosis. In aged tissues, where mitochondrial dysfunction is a hallmark of cellular decline, SS-31 effectively rejuvenates mitochondrial function toward a younger phenotype. Clinical studies have shown improvements in skeletal muscle energetics, cardiac function, and exercise tolerance in elderly subjects and patients with mitochondrial myopathy.